Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood (2024) 143 (22): 2256–2269.

https://doi.org/10.1182/blood.2023021864

Published: 2024

Includes: Supplemental data

Journal Articles

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Alok Srivastava, Savita Rangarajan, Kaan Kavakli, Robert Klamroth, Gili Kenet, Liane Khoo, Chur-Woo You, Weiqun Xu, Niel Malan, Laurent Frenzel, Catherine N. Bagot, Oleksandra Stasyshyn, Chia-Yau Chang, Stacey Poloskey, Shauna Andersson, Zhiying Qiu, Baisong Mei, Steven W. Pipe

Blood (2021) 138 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2021-155018

Published: 2021

Journal Articles

Extrinsic Venous Compression May Not Be a Sufficient Explanation for Venous Thromboembolism Due to Massive Fibroids.

Sarah Barsam, MBBS, MRCP, Catherine N. Bagot, MBBS MD MRCP, Raj K. Patel, MD MRCP MRCPath, Paul S. Sidhu, MRCP FRCR, Anthony Davies, MB BChir MRCOG, Roopen Arya, PhD FRCP FRCPath

Blood (2006) 108 (11): 4100.

https://doi.org/10.1182/blood.V108.11.4100.4100

Published: 2006

Journal Articles

Low Dose Prothrombin Complex Concentrates Reverse Oral Anticoagulation with Minimal Complications.

Catherine N. Bagot, MBBS, MD, MRCP, Jaimal Kothari, MBBS, MRCP, Raj K. Patel, MD, MRCP, MRCPath, Roopen Arya, PhD, FRCP, FRCPath

Blood (2006) 108 (11): 891.

https://doi.org/10.1182/blood.V108.11.891.891

Published: 2006

Journal Articles

The Outcome of Lymphoproliferative Disorder in Liver Transplant Recipients May Correlate with Age at Diagnosis and the Use of Chemotherapy: A Single Centre Report.

Catherine N. Bagot, MBBS, MD, Austin Kulasekararaj, Sandeep Ramalingam, Nigel Heaton, John O’Grady, Dino Hadzic, Bernard Portmann, Mohamed Rela, Jon Salisbury, Steven Devereux, Ghulam J. Mufti, Antonio Pagliuca

Blood (2005) 106 (11): 1435.

https://doi.org/10.1182/blood.V106.11.1435.1435

Published: 2005

NARROW

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Extrinsic Venous Compression May Not Be a Sufficient Explanation for Venous Thromboembolism Due to Massive Fibroids.

Low Dose Prothrombin Complex Concentrates Reverse Oral Anticoagulation with Minimal Complications.

The Outcome of Lymphoproliferative Disorder in Liver Transplant Recipients May Correlate with Age at Diagnosis and the Use of Chemotherapy: A Single Centre Report.

Email alerts

ASH Publications

American Society of Hematology

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Extrinsic Venous Compression May Not Be a Sufficient Explanation for Venous Thromboembolism Due to Massive Fibroids.

Low Dose Prothrombin Complex Concentrates Reverse Oral Anticoagulation with Minimal Complications.

The Outcome of Lymphoproliferative Disorder in Liver Transplant Recipients May Correlate with Age at Diagnosis and the Use of Chemotherapy: A Single Centre Report.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only